Nyxoah S.A.
NYXH
$-0.12
Change (1 day)
$20.00
Year High
$4.00
Year Low
Categories
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
P/B ratio for Nyxoah S.A. (NYXH)
P/B ratio as of 2023: 1.20
According to Nyxoah S.A.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.20. At the end of 2022 the company had a P/B ratio of 1.00.
P/B ratio history for Nyxoah S.A. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.20 |
| 2022 | 1.00 |
| 2021 | 3.24 |
| 2020 | 3.66 |
| 2019 | 123.48 |
| 2018 | 41.83 |
| 2017 | 92.27 |